Entropy Technologies’s Avadel Pharmaceuticals AVDL Stock Holding History

Entropy Technologies’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-23,952	Closed	-$516K	–	889
2025 Q4	$516K	Buy	+23,952	New	+$465K	0.03%	553

Other funds holding AVDL

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Entropy Technologies's AVDL Position: Q1 2026 in Review

Entropy Technologies sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 23,952 shares — an estimated $516K sold.

Entropy Technologies first reported a position in AVDL in Q4 2025 and held it in 1 quarter. The position peaked at $516K in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

Entropy Technologies reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Entropy Technologies sold 23,952 Avadel Pharmaceuticals shares in Q1 2026, an estimated $516K.
Entropy Technologies first reported a position in Avadel Pharmaceuticals in Q4 2025 and held it in 1 quarter.
Entropy Technologies's Avadel Pharmaceuticals position peaked at $516K in Q4 2025.
2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Entropy Technologies's 13F filing for Q1 2026, filed 14 May 2026.